Early 2012 Uptick Expected for Dendreon's (DNDN) Provenge
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 15 | New: 18
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 15 | New: 18
Trade Now!
Join SI Premium – FREE
Deutsche Bank commented on Dendreon (NASDAQ: DNDN) Thursday following a meeting with CFO Greg Schiffman.
The firm came away from the meeting with the feeling that doctors will become more comfortable with Provenge reimbursement in the 1st-half of 2012, which will drive a "significant uptick."
"According to the CFO, many centers are saying they want to see 4-6 patients are FULLY reimbursed before adding more patients/month. They think a cycle takes on average 2.5 months to perscribe, treat, & reimburse," the analyst commented.
They note that Q4 is typically the weakest quarter, because few days doctors work/infuse.
A final J-code list comes out in November, although the company doesn't expect Provenge to be on the list. The should come in the next preliminary J-code list out mid-year 2012. However, checks with doctors indicate reimbursement speed with Q-code is sufficient.
Deutsche Bank said the bottom line is that the company is finally putting a marketing plan in place that should get results over time.
The firm maintained a Buy rating and price target of $20 on DNDN, suggesting 122 percent upside from Wednesday's clsoe.
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $9.00 yesterday.
The firm came away from the meeting with the feeling that doctors will become more comfortable with Provenge reimbursement in the 1st-half of 2012, which will drive a "significant uptick."
"According to the CFO, many centers are saying they want to see 4-6 patients are FULLY reimbursed before adding more patients/month. They think a cycle takes on average 2.5 months to perscribe, treat, & reimburse," the analyst commented.
They note that Q4 is typically the weakest quarter, because few days doctors work/infuse.
A final J-code list comes out in November, although the company doesn't expect Provenge to be on the list. The should come in the next preliminary J-code list out mid-year 2012. However, checks with doctors indicate reimbursement speed with Q-code is sufficient.
Deutsche Bank said the bottom line is that the company is finally putting a marketing plan in place that should get results over time.
The firm maintained a Buy rating and price target of $20 on DNDN, suggesting 122 percent upside from Wednesday's clsoe.
For more ratings news on Dendreon click here and for the rating history of Dendreon click here.
Shares of Dendreon closed at $9.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Sees Slower Margin Expansion Lightspeed POS Inc. (LSPD) PT Lowered to $31
- Future PLC (FUTR:LN) PT Lowered to GBP27.50 at Barclays
- UPDATE: BofA Securities Downgrades Pure Storage (PSTG) to Neutral; Cautious on Storage Demand
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
